Please cancel the present "SEQUENCE LISTING", pages 34-39, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 to 5, at the end of the application. Cancel the page numbers for the Claims and Abstract and renumber, accordingly.

REMARKS

Applicant requests entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequences, SEQ ID NOS:1-7, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy.

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
FJM:dmw

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

Paragraph beginning at line 30 of page 16 has been amended as follows:

In a preferred embodiment, the present invention provides a chimeric protein described above, wherein the second peptidyl fragment consists of the amino acid sequence of SEQ ID NO:3 ~~SEQ ID:3~~.

Paragraph beginning at line 26 of page 25 has been amended as follows:

In a preferred embodiment, the present invention provides a process for obtaining a correctly folded insulin-precursor-containing chimeric protein described above, wherein the cleavable amino acid residue is an Arg or a Lys residue. Also preferably, the cleavable amino acid residues consist of the amino acid sequence of SEQ ID NO:3 ~~SEQ ID:3~~.

Paragraph beginning at line 30 of page 29 has been amended as follows:

A DNA fragment encoding the hGH-mini-proinsulin consisting of the amino acid sequence of SEQ ID NO:6 was chemically synthesized according to the procedure disclosed in Gan et al., *Gene*, 1989, 79:159-166. A 5' Cla I site and a 3' Hind III site were included in the synthesized DNA fragment. Briefly, a fragment from the 5' Cla I to 3' Kpn I, which cuts the nucleotide sequence encoding amino acid residues 51 and 52 of the SEQ ID NO:6, and a fragment from 5' Kpn I to 3' ~~3'~~ Hind III were chemically synthesized and subcloned into a pUC18 vector, respectively. Subsequently, the DNA fragment encoding the entire amino acid sequence of SEQ ID NO:6 ~~SEQ ID:6~~

was subcloned into a modified pATH2 vector such that expression of the hGH-mini-proinsulin was under the control of a Trp promoter and a SD sequence. The resulting vector, pZRhi-1 (Figure 2) was used to express the hGH-mino proinsulin fusion protein.